Dr. Mamunur Rashid completed his education at Jawaharlal Nehru University, India, while concurrently working at the CSIR Central Drug Research Institute, India, specializing in Biological Sciences with a focus on Pharmacokinetics & Pharmaceutics. He earned his bachelor’s degree (B.Sc.) in Biochemistry and his Master's (M.Sc.) in Biotechnology from Aligarh Muslim University, India. Dr. Rashid's research primarily centers on preclinical pharmacokinetics, encompassing bioavailability, dose-proportionality, species variation, and allometric scaling. This work informs preclinical studies, addressing the early impacts of pharmacokinetics in drug discovery. His investigations aim to elucidate the molecular mechanisms of ADME (absorption, distribution, metabolism, and excretion) and the interactions of novel compounds with drug-metabolizing enzymes. This involves assessing metabolic stability, the formation of reactive metabolites, mass fragmentation, metabolite identification, enzyme kinetics, drug transport, and permeability across biological barriers. To facilitate his research, Dr. Rashid employs cutting-edge analytical instruments with over 8 years of experience in pharmacokinetics; he demonstrates expertise in operating a wide range of LC-MS/MS instruments, including AB Sciex (Qtrap 5500, 4000, 3200), Bruker EVOQ Elite, Shimadzu NX 8060, Shimadzu 8050, and Waters Xevo TQ-S LC-MS) for both clinical and nonclinical sample analysis.
Dr. Mamunur Rashid completed his education at Jawaharlal Nehru University, India, while concurrently working at the CSIR Central Drug Research Institute, India, specializing in Biological Sciences with a focus on Pharmacokinetics & Pharmaceutics. He earned his bachelor’s degree (B.Sc.) in Biochemistry and his Master's (M.Sc.) in Biotechnology from Aligarh Muslim University, India. Dr. Rashid's research primarily centers on preclinical pharmacokinetics, encompassing bioavailability, dose-proportionality, species variation, and allometric scaling. This work informs preclinical studies, addressing the early impacts of pharmacokinetics in drug discovery. His investigations aim to elucidate the molecular mechanisms of ADME (absorption, distribution, metabolism, and excretion) and the interactions of novel compounds with drug-metabolizing enzymes. This involves assessing metabolic stability, the formation of reactive metabolites, mass fragmentation, metabolite identification, enzyme kinetics, drug transport, and permeability across biological barriers. To facilitate his research, Dr. Rashid employs cutting-edge analytical instruments with over 8 years of experience in pharmacokinetics; he demonstrates expertise in operating a wide range of LC-MS/MS instruments, including AB Sciex (Qtrap 5500, 4000, 3200), Bruker EVOQ Elite, Shimadzu NX 8060, Shimadzu 8050, and Waters Xevo TQ-S LC-MS) for both clinical and nonclinical sample analysis.